Oniria Therapeutics is a biotech company focused in the field of precision oncology. It develops first-in-class therapies to modulate and eliminate dormant tumor cells as a novel targeted strategy to overcome their persistence. Our flagship product, ONR-001 is an oral small molecule that allosterically activates TET2, a master epigenetic enzyme, causing tumor cells to enter a dormant state and even die. It is indication agnostic and can be used at all stages of the disease. Currently we have selected the final candidate and we have results of in-vivo efficacy in xenofraft models of Acute Myeloid Leukemia, Melanoma and Colorectal Cancer.